GlassScriptPhysician profile
Kimberley A Drayton
NPI 1386767226
$6,426.47
in general payments reported to CMS, 2019-2025
47 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $1,123 · 2021: $1,025 · 2022: $970 · 2023: $1,057 · 2024: $1,009 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,192.23 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $550.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $493.87 | 2021-2025 | Ubrelvy, Vraylar |
| Amgen INC. | $396.97 | 2019-2024 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $375.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $325.97 | 2020-2024 | Gardasil 9, Verquvo, Capvaxive |
| Pfizer INC. | $279.15 | 2019-2025 | |
| Allergan, INC. | $242.19 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $216.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $190.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $182.99 | 2019-2025 | |
| Amarin Pharma, INC. | $171.93 | 2019-2021 | |
| Abbott Laboratories | $167.01 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $155.79 | 2019-2022 | |
| Astellas Pharma US INC | $151.62 | 2019-2024 | Veozah |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Drayton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.